they're virtually superimposable. You might say, well, this is just the average results. By the way, the averages were -- if you would look at the ratios there, they're just about a 100 percent exactly, and you might say, what about variability? The variability here was very small. In fact, for the total T4, I think the variability was around 10 percent CV which is a really low variability drug, which is very good because we have a narrow therapeutic index drug.
Next slide, please. This is a study of the generic or the new preparation prepared by Geneva versus Synthroid. This was the result of the typical study. The top slide gives you the average results for total T4 and the bottom slide is the corrected T4, and I can tell you for the total T4, the CV was less than 10 percent. I'm going to show you more about that in just a moment.
Next slide, please. Here's another study done against Levoxyl. Again, this is just a head-to-head study, typical bioequivalence study, virtually superimposable average blood levels. The ratio of Cmax and AUC again for this was very close to 100 percent, like 101, 102, something like that, very low variability.